Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma

1

Bendamustine lymphodepletion prior to BCMA CAR-T therapy was evaluated against the standard fludarabine/cyclophosphamide regimen.
2

A total of 56 patients were included, with 14 receiving bendamustine and 42 receiving fludarabine/cyclophosphamide for CAR-T therapy.
3

Bendamustine achieved effective lymphodepletion, with higher absolute lymphocyte counts compared to fludarabine/cyclophosphamide on the day of CAR-T infusion.
4

There were no significant differences in CAR-T expansion or response rates between the bendamustine and fludarabine/cyclophosphamide groups.
5

The study highlights the potential of bendamustine as an alternative lymphodepletion agent during fludarabine shortages in CAR-T therapy.

Blood Cancer Journal

by Surbhi Sidana, Hitomi Hosoya, Alexandria Jensen, Lawrence Liu, Anmol Goyal, Vanna Hovanky, Bita Sahaf, Sushma Bharadwaj, Theresa Latchford, Sally Arai, Sheryl Leahy, Matthew Mei, Lihua E. Budde, Lori S. Muffly, Matthew J. Frank, Saurabh Dahiya, Myo Htut, David Miklos, Murali Janakiram
October 13, 2023

1